Furthermore, mutations in genes involved in signaling pathways like FLT3, KIT, KRAS, NRAS might be sub-clonal and have a low negative predictive value, according to 2021 and 2024 ELN updates for MDS and AML, even though they could indicate the presence of residual AML cells. The gene discussed is KRAS; the disease is acute myeloid leukemia.